Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
CpG-ODN
adjuvant
cancer immunotherapy
immune checkpoint blockade
innate immune
toll-like receptor
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
02
2020
accepted:
04
05
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
17
4
2021
Statut:
epublish
Résumé
Immunotherapy using checkpoint blockade has revolutionized cancer treatment, improving patient survival and quality of life. Nevertheless, the clinical outcomes of such immunotherapy are highly heterogeneous between patients. Depending on the cancer type, the patient response rates to this immunotherapy are limited to 20-30%. Based on the mechanism underlying the antitumor immune response, new therapeutic strategies have been designed with the aim of increasing the effectiveness and specificity of the antitumor immune response elicited by checkpoint blockade agents. The activation of toll-like receptor 9 (TLR9) by its synthetic agonists induces the antitumor response within the innate immunity arm, generating adjuvant effects and priming the adaptive immune response elicited by checkpoint blockade during the effector phase of tumor-cell killing. This review first describes the underlying mechanisms of action and current status of monotherapy using TLR9 agonists and immune checkpoint inhibitors for cancer immunotherapy. The rationale for combining these two agents is discussed, and evidence indicating the current status of such combination therapy as a novel cancer treatment strategy is presented.
Identifiants
pubmed: 32547560
doi: 10.3389/fimmu.2020.01075
pmc: PMC7274158
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Oligodeoxyribonucleotides
0
Toll-Like Receptor 9
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1075Informations de copyright
Copyright © 2020 Chuang, Tseng, Huang, Huang, Huang and Chuang.
Références
J Cell Mol Med. 2010 Nov;14(11):2592-603
pubmed: 20629986
Science. 2001 Jan 12;291(5502):319-22
pubmed: 11209085
Front Immunol. 2018 Mar 16;9:516
pubmed: 29616030
Cancer Res. 2004 Aug 1;64(15):5074-7
pubmed: 15289307
Nucleic Acid Ther. 2015 Jun;25(3):130-40
pubmed: 25826686
Oncogene. 2010 Dec 2;29(48):6301-13
pubmed: 20856204
Immunotherapy. 2014;6(10):1085-95
pubmed: 25428647
J Immunol. 1999 May 15;162(10):5813-20
pubmed: 10229815
Eur J Pharmacol. 2009 Dec 25;625(1-3):41-54
pubmed: 19837059
Eur Cytokine Netw. 2000 Sep;11(3):362-71
pubmed: 11022119
J Immunol. 2002 May 15;168(10):4907-13
pubmed: 11994440
Semin Oncol. 2019 Aug - Oct;46(4-5):385-392
pubmed: 31739997
Expert Rev Clin Immunol. 2017 Oct;13(10):1001-1015
pubmed: 28795649
Gastroenterol Hepatol (N Y). 2019 May;15(5):266-272
pubmed: 31360140
Nat Immunol. 2006 May;7(5):498-506
pubmed: 16604075
Semin Oncol. 2017 Apr;44(2):132-135
pubmed: 28923211
Clin Cancer Res. 2003 Jul;9(7):2693-700
pubmed: 12855649
J Natl Cancer Inst. 1984 Apr;72(4):955-62
pubmed: 6200641
J Clin Invest. 2007 May;117(5):1184-94
pubmed: 17476348
Future Oncol. 2018 Feb;14(5):417-430
pubmed: 29094609
Adv Drug Deliv Rev. 2008 Apr 29;60(7):795-804
pubmed: 18262306
J Immunother Cancer. 2019 Nov 26;7(1):323
pubmed: 31771649
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):588-93
pubmed: 9435236
Ann Oncol. 2012 Jan;23(1):72-7
pubmed: 21464154
Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(3):153-160
pubmed: 29526974
Immunity. 1994 Dec;1(9):793-801
pubmed: 7534620
Clin Cancer Res. 2019 Feb 15;25(4):1185-1195
pubmed: 30093453
Oncoimmunology. 2019 Jul 18;8(11):e1638212
pubmed: 31646087
JCI Insight. 2017 Sep 21;2(18):
pubmed: 28931759
Int J Nanomedicine. 2012;7:2181-95
pubmed: 22619554
J Am Acad Dermatol. 2010 Dec;63(6):975-83
pubmed: 20888065
Front Immunol. 2019 Dec 17;10:2965
pubmed: 31921205
Curr Top Microbiol Immunol. 2017;410:75-97
pubmed: 28929192
World J Gastrointest Oncol. 2018 May 15;10(5):108-114
pubmed: 29770170
Cancer Discov. 2018 Jun;8(6):670
pubmed: 29669722
Annu Rev Immunol. 2002;20:709-60
pubmed: 11861616
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
J Leukoc Biol. 2013 Nov;94(5):885-902
pubmed: 23990624
Oncotarget. 2017 Oct 31;8(62):106132-106142
pubmed: 29285320
Nature. 2000 Dec 7;408(6813):740-5
pubmed: 11130078
J Exp Med. 2006 Aug 7;203(8):1999-2008
pubmed: 16864658
Expert Opin Investig Drugs. 2011 Mar;20(3):361-72
pubmed: 21254877
Nat Immunol. 2001 Aug;2(8):675-80
pubmed: 11477402
Front Immunol. 2012 Apr 18;3:79
pubmed: 22566960
Clin Genitourin Cancer. 2009 Oct;7(3):E58-65
pubmed: 19815483
Ann Oncol. 2017 Feb 1;28(2):298-304
pubmed: 27831503
Nat Rev Immunol. 2008 Aug;8(8):594-606
pubmed: 18641647
J Clin Oncol. 2008 Aug 20;26(24):3979-86
pubmed: 18711188
J Exp Med. 2001 Apr 2;193(7):839-46
pubmed: 11283156
Science. 2004 Mar 5;303(5663):1526-9
pubmed: 14976262
Contemp Oncol (Pozn). 2018 Mar;22(1A):56-60
pubmed: 29628795
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9305-10
pubmed: 10430938
Cancer Sci. 2009 May;100(5):934-9
pubmed: 19245434
Biomedicines. 2014 Aug 04;2(3):211-228
pubmed: 28548068
Cancer Commun (Lond). 2019 Jun 14;39(1):34
pubmed: 31200766
Nat Immunol. 2005 Nov;6(11):1087-95
pubmed: 16186825
Nat Rev Immunol. 2004 Apr;4(4):249-58
pubmed: 15057783
Int Immunol. 2001 Jul;13(7):933-40
pubmed: 11431423
Blood. 2016 Mar 31;127(13):1687-700
pubmed: 26796361
J Clin Oncol. 2011 Jul 1;29(19):2667-74
pubmed: 21632509
Nature. 1999 Oct 21;401(6755):811-5
pubmed: 10548109
Immunity. 1994 Aug;1(5):405-13
pubmed: 7882171
Future Oncol. 2018 Aug;14(18):1869-1874
pubmed: 29473436
Cancer Discov. 2018 Aug;8(8):904
pubmed: 29967015
Nat Immunol. 2005 Aug;6(8):769-76
pubmed: 15995707
J Natl Cancer Inst. 2019 Nov 1;111(11):1131-1141
pubmed: 31322663
J Immunother. 2010 Apr;33(3):225-35
pubmed: 20445343
J Immunol Res. 2017;2017:7807313
pubmed: 28894754
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Cancer Discov. 2017 Jul;7(7):659-660
pubmed: 28546286
Cancer Discov. 2016 Aug;6(8):811
pubmed: 27325283
Int J Clin Oncol. 2020 May;25(5):790-800
pubmed: 31900651
Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40
pubmed: 11763350
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Front Immunol. 2019 Apr 02;10:604
pubmed: 31001249
J Immunol. 2011 Apr 15;186(8):4794-804
pubmed: 21398612
Science. 2002 Dec 13;298(5601):2199-202
pubmed: 12481138
Cancer Discov. 2017 Jun;7(6):OF5
pubmed: 28438774
Curr Opin Immunol. 2010 Feb;22(1):20-7
pubmed: 20060278
Biochem Soc Trans. 2007 Dec;35(Pt 6):1461-7
pubmed: 18031246
Blood. 1997 Apr 15;89(8):2994-8
pubmed: 9108420
J Hematol Oncol. 2019 Sep 4;12(1):89
pubmed: 31484560
Cancers (Basel). 2019 Nov 08;11(11):
pubmed: 31717326
JAMA Oncol. 2018 Feb 1;4(2):157-158
pubmed: 29285544
Nature. 2005 Mar 10;434(7030):243-9
pubmed: 15665823
Nature. 2001 Oct 18;413(6857):732-8
pubmed: 11607032
Drugs. 2011 May 28;71(8):1093-104
pubmed: 21668044
J Immunother. 2008 Jun;31(5):520-7
pubmed: 18463532
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Cancer Res. 2018 Sep 1;78(17):4943-4956
pubmed: 29945961
Springer Semin Immunopathol. 2000;22(1-2):21-33
pubmed: 10944797
Cancer Discov. 2016 Dec;6(12):OF1
pubmed: 27920140
Nature. 2001 Apr 26;410(6832):1099-103
pubmed: 11323673
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
Cancer Biol Med. 2015 Sep;12(3):201-8
pubmed: 26487965
Gene. 1999 Apr 29;231(1-2):59-65
pubmed: 10231569
Immunol Lett. 2002 Oct 1;83(3):215-20
pubmed: 12095712
Front Immunol. 2018 Jun 01;9:1082
pubmed: 29910800
J Natl Cancer Inst. 1985 Mar;74(3):681-8
pubmed: 3856070
Semin Cancer Biol. 2020 Aug;64:61-82
pubmed: 31054927
Cancer Discov. 2015 May;5(5):OF1
pubmed: 25835401
Nucleic Acids Res. 1991 Feb 25;19(4):747-50
pubmed: 1850122
Oncoimmunology. 2015 Sep 2;5(3):e1088631
pubmed: 27141345
Oncoimmunology. 2019 Sep 20;8(12):e1659096
pubmed: 31741757
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71
pubmed: 11698646
Nat Rev Immunol. 2016 Jan;16(1):35-50
pubmed: 26711677
Curr Opin Immunol. 2007 Feb;19(1):1-3
pubmed: 17157490
Handb Exp Pharmacol. 2008;(183):51-70
pubmed: 18071654
Curr Oncol Rep. 2018 Feb 7;20(1):8
pubmed: 29411148
PLoS One. 2014 Sep 30;9(9):e108808
pubmed: 25269083
Drug Resist Updat. 2017 Jan;30:39-47
pubmed: 28363334
Adv Drug Deliv Rev. 2009 Mar 28;61(3):195-204
pubmed: 19211030
Oligonucleotides. 2010 Apr;20(2):93-101
pubmed: 20384481
Int Rev Immunol. 2017 Mar 4;36(2):57-73
pubmed: 28060562
Cancer Lett. 2019 Aug 1;456:23-28
pubmed: 30959079
J Exp Med. 2000 Aug 21;192(4):595-600
pubmed: 10952730
Springer Semin Immunopathol. 2000;22(1-2):11-9
pubmed: 10944796
Int J Dermatol. 2016 Aug;55(8):831-44
pubmed: 27387373
Nature. 2001 Jul 19;412(6844):346-51
pubmed: 11460167
Annu Rev Immunol. 2006;24:353-89
pubmed: 16551253
Drugs. 2014 Oct;74(16):1973-1981
pubmed: 25331768
Nature. 2005 Apr 21;434(7036):1035-40
pubmed: 15815647
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
J Immunol. 2002 Feb 1;168(3):1212-8
pubmed: 11801657
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Cancer Discov. 2019 May;9(5):568-569
pubmed: 30910909
J Leukoc Biol. 2019 Jul;106(1):147-160
pubmed: 30900780
Cancer Res. 2003 Jun 15;63(12):3281-8
pubmed: 12810660
Mediators Inflamm. 2010;2010:
pubmed: 20706656
Oncologist. 2017 Jul;22(7):873-878
pubmed: 28533473
Biochim Biophys Acta. 2001 Mar 19;1518(1-2):157-61
pubmed: 11267672
Therapy. 2009 May 1;6(3):433-442
pubmed: 20161373
Oncogene. 2008 Jan 7;27(2):161-7
pubmed: 18176597
Nat Immunol. 2004 Feb;5(2):190-8
pubmed: 14716310
Curr Opin Immunol. 2017 Apr;45:43-51
pubmed: 28192720
Eur J Immunol. 2004 Jan;34(1):251-62
pubmed: 14971051
Nat Immunol. 2002 Jul;3(7):611-8
pubmed: 12087419
Cancer Discov. 2017 Jun;7(6):OF4
pubmed: 28446440
J Immunol. 2003 Oct 15;171(8):3941-6
pubmed: 14530311
Sci Signal. 2018 May 01;11(528):
pubmed: 29717061
J Immunol. 2002 Sep 1;169(5):2368-73
pubmed: 12193703
Cancer Discov. 2019 May;9(5):OF2
pubmed: 30894361
Cancer Cell. 2018 Apr 9;33(4):581-598
pubmed: 29634946
J Leukoc Biol. 2002 May;71(5):813-20
pubmed: 11994506
J Immunol. 2002 Jul 1;169(1):10-4
pubmed: 12077222
Nat Immunol. 2004 Oct;5(10):1061-8
pubmed: 15361868
J Exp Med. 2007 May 14;204(5):1013-24
pubmed: 17485511
Nat Med. 1997 Aug;3(8):849-54
pubmed: 9256274
Trends Microbiol. 2000 Oct;8(10):452-6
pubmed: 11044679
Adv Immunol. 1999;73:329-68
pubmed: 10399010
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Trends Immunol. 2018 Nov;39(11):921-936
pubmed: 30309702
Cancer Discov. 2018 Oct;8(10):1250-1257
pubmed: 30154193
Prog Nucleic Acid Res Mol Biol. 1981;25:33-52
pubmed: 6261297
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249
pubmed: 27799536
Oncoimmunology. 2018 Oct 11;7(12):e1526250
pubmed: 30524908
Science. 2004 Mar 5;303(5663):1529-31
pubmed: 14976261
Clin Drug Investig. 2018 Oct;38(10):883-899
pubmed: 30128748
Eur Cytokine Netw. 2000 Sep;11(3):372-8
pubmed: 11022120
Expert Opin Biol Ther. 2018 Sep;18(9):947-957
pubmed: 30124333
World J Gastroenterol. 2005 Feb 28;11(8):1220-4
pubmed: 15754409
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Science. 2010 Sep 17;329(5998):1530-4
pubmed: 20847273
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42
pubmed: 11470918
Cancer Discov. 2018 Dec;8(12):OF2
pubmed: 30377167
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
Br J Cancer. 2015 Apr 28;112(9):1421-7
pubmed: 25856776
Methods Mol Biol. 2017;1494:15-27
pubmed: 27718183
J Immunother Cancer. 2019 May 2;7(1):116
pubmed: 31046839
J Biol Chem. 2005 Mar 4;280(9):8086-93
pubmed: 15591070
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Curr Cancer Drug Targets. 2018;18(2):124-138
pubmed: 28464762
Science. 1999 Jul 30;285(5428):736-9
pubmed: 10426996
Eur J Cancer. 2004 May;40(8):1275-81
pubmed: 15110894
Nucleic Acids Res. 1988 Apr 25;16(8):3209-21
pubmed: 2836790
Oncoimmunology. 2014 Jan 1;3(1):e27441
pubmed: 24800162
Nature. 2005 Apr 7;434(7034):772-7
pubmed: 15800576
J Immunother Cancer. 2019 Apr 18;7(1):109
pubmed: 30999964
BioDrugs. 2007;21(6):387-401
pubmed: 18020622
J Exp Med. 1991 Sep 1;174(3):561-9
pubmed: 1714933
Sci Rep. 2016 Mar 30;6:23771
pubmed: 27026194
Future Oncol. 2018 Apr;14(10):907-917
pubmed: 29260582
Blood. 2004 Mar 15;103(6):2162-9
pubmed: 14630815
Oncologist. 2016 May;21(5):643-50
pubmed: 27026676
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Pharmacol Ther. 2019 Feb;194:84-106
pubmed: 30268773
Biochem Soc Trans. 2007 Dec;35(Pt 6):1468-72
pubmed: 18031247
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83
pubmed: 8610135
J Immunol. 1996 Sep 1;157(5):1840-5
pubmed: 8757300
Science. 1998 Dec 11;282(5396):2085-8
pubmed: 9851930
Adv Physiol Educ. 2013 Dec;37(4):284-91
pubmed: 24292903
J Leukoc Biol. 2002 Mar;71(3):538-44
pubmed: 11867692
Expert Opin Biol Ther. 2019 Sep;19(9):927-935
pubmed: 31272242
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
Curr Pharm Des. 2016;22(41):6234-6250
pubmed: 27568731
Cancer Res. 2005 Jul 15;65(14):6388-93
pubmed: 16024642
J Clin Oncol. 2006 Dec 20;24(36):5716-24
pubmed: 17179105
Cell. 2000 Oct 13;103(2):351-61
pubmed: 11057907
Vaccine. 2019 Sep 16;37(39):5854-5861
pubmed: 31431412
Nature. 1995 Apr 6;374(6522):546-9
pubmed: 7700380
Nat Rev Urol. 2018 Oct;15(10):615-625
pubmed: 29991725
Cancer. 2009 Sep 1;115(17):3944-54
pubmed: 19536884
Oligonucleotides. 2006 Winter;16(4):313-22
pubmed: 17155907
Cancer Discov. 2017 May;7(5):OF1
pubmed: 28363910
Immunity. 2018 Mar 20;48(3):417-433
pubmed: 29562193
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846
pubmed: 29420123